Table 1.
Participant demographics.
| TRD | Healthy controls | t/χ2 | p | |
|---|---|---|---|---|
| N | 66 | 32 | – | – |
| Age (years) | 39.5 ± 11.1 | 35.03 ± 12.2 | −1.8 | 0.08 |
| Sex | 31M/35F | 17M/32F | 0.33 | 0.56 |
| Race – White, Non-Hispanic | 66.6% | 26% | – | – |
| Race – White, Hispanic | 10.1% | 17.9% | – | – |
| Race – Asian | 10.1% | 17.9% | – | – |
| Race – Black | 3% | 20.5% | – | – |
| Race – More than 1 | 3% | 7.7% | – | – |
| Duration of lifetime illness (years) | 24.5 ± 15.5 | – | – | – |
| Age of onset (years old) | 16.6 ± 8.4 | – | – | – |
| Pre-treatment HDRS | 19 ± 4.9 | – | – | – |
| Pre-treatment composite crystallized neurocognitive function | 57.3 ± 9.4 | – | – | – |
| Pre-treatment composite fluid neurocognitive function | 47.3 ± 9.2 | – | – | – |